Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells

European Journal of Endocrinology

Volumn 142, Issue 6, 2000, Pages 661-664

  Kanzawa, Michiko ^a   Sugimoto, Toshitsugu ^a   Kanatani, Masanori ^a   Chihara, Kazuo ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; PARATHYROID HORMONE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; ENZYME ACTIVITY; HORMONAL REGULATION; MOUSE; NONHUMAN; NORTHERN BLOTTING; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0034044832     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1420661     Document Type: Article

References (22)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 509-519.
2. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T et al. Isolation of a novel cytokine from human fibroblasls that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 1997 254 157-142.
3. Mizuno A, Amizuka N, Irie K, Murakarni A, Fujise N, Kanno T et al. Severe osteoporosis in mice lacking ostroclastogenesis inhibitory factor/ostcoprotegerin. Biochemical and Biophysical Research Communications 1998 247 610-615.
4. 2 in human bone marrow stroma cells. Biochemical and Biophysical Research Communications 1998 247 338-341.
5. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL & Khosla S. Osteoprotegerin proctuction by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenic protein-2, and cytokines. Biochemical and Biophysical Research Communications 1998 250 776-781.
6. Vidal NOA, Sjogren K, Eriksson BI, Ljunggren Ö & Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochemical and Biophysical Research Communications 1998 248 696-700.
7. Brändström H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C & Ljunggren Ö. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-65 cells. Biochemical and Biophysical Research Communications 1998 248 454-457.
8. Vidal NOA, Brandstrom H, Jonsson KB & Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. Journal of Endocrinology 1998 159 191-195.
9. Horwood NJ, Elliott J, Martin J & Gillespie MT. Osteotropic agents regulate the expression of osleoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998 139 4743-4746.
10. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. Journal of Biological Chemistry 1998 273 27091-27096.
11. Lee S-K & Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999 140 3552-3561.
12. Murakami T, Yamamoto M, Yamamoto M, Ono K, Nishikawa M, Nagata N et al. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/ stromal cells and inhibits the survival of murine osteoclast-like cells. Biochemical and Biophysical Research Communications 1998 252 747-752.
13. Kaji H, Sugimoto T, Kanatani M, Fukase M & Chihara K. Involvement of dual signal transduction systems in the stimulation of osteoclast-like cell formation by parathyroid hormone and parathyroid hormone-related peptide. Biochemical und Biophysical Research Communications 1993 194 157-152.
14. Kaji H, Sugimoto T, Kanatani M, Nasu M & Chihara K. Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway. Endocrinology 1996 137 2217-2224.
15. Chomczynski P & Sacchi N. Single-step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987 162 156-159.
16. Abou-Samra AB, Jüppner H, Force T, Freeman MW, Kong XF, Schipani E et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proceedings of the National Academy of Sciences of the USA 1992 89 2732-2736.
17. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT & Martin TJ. Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endocrine Reviews 1999 20 345-357.
18. Itoh K, Shinki T, Udagawa N, Ueno Y, Matsuzaki K, Yakahashi N et al. The mechanism of osteoclastogenesis induced by PTH. Journal of Bone Mineral Research 1999 14 (Suppl 1) SU205.
19. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165-176.
20. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the USA 1998 95 3597-3602
21. Fuller K, Wong B, Fox S, Choi Y & Chambers TJ. TRANCK is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. Journal of Experimental Medicine 1998 188 997-1001.
22. Suda T, Takahashi N & Martin TJ. Modulation of osteoclast differentiation. Endocrine Reviews 1992 13 66-80.